Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director comp.
Director departure
eFFECTOR Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/18/2023 SC 13D/A Carlyle Group Inc. reports a 7.8% stake in eFFECTOR Therapeutics, Inc.
08/08/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/08/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update"
08/04/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/04/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
06/16/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
06/08/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
06/08/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Form of Pre-Funded Warrant",
"Form of Common Warrant",
"Form of Wainwright Warrant",
"Legal Opinion of Latham & Watkins LLP",
"Form of Securities Purchase Agreement",
"eFFECTOR Therapeutics Announces $8.7 Million Registered Direct Offering Priced At- The-Market Under Nasdaq Rules"
06/08/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/30/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/30/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Form of Pre-Funded Warrant",
"Form of Common Warrant",
"Form of Wainwright Warrant",
"Legal Opinion of Latham & Watkins LLP",
"Form of Securities Purchase Agreement",
"eFFECTOR Therapeutics Announces $7.5 Million Registered Direct Offering Priced At- The-Market Under Nasdaq Rules"
05/25/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/25/2023 8-K Other Events  Interactive Data
05/19/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/19/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/12/2023 ARS Form ARS - Annual Report to Security Holders:
05/12/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/12/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/09/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "eFFECTOR Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update"
04/27/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/17/2023 EFFECT Form EFFECT - Notice of Effectiveness:
03/10/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/08/2023 10-K Annual Report for the period ended December 31, 2022
03/08/2023 8-K Quarterly results
Docs: "eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update"
03/07/2023 SC 13G Altitude Life Science Ventures Fund II, L.P. reports a 6.7% stake in eFFECTOR Therapeutics, Inc.
03/06/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
03/06/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
02/14/2023 SC 13G/A Empyrean Capital Partners, LP reports a 0% stake in eFFECTOR Therapeutics, Inc.
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/05/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy